Status:
UNKNOWN
Efficacy of Neoadjuvant Therapy With Cisplatin Plus Mitomycin C in BRCA1-Mutated Ovarian Cancer
Lead Sponsor:
N.N. Petrov National Medical Research Center of Oncology
Conditions:
Ovarian Cancer
Eligibility:
FEMALE
18-75 years
Phase:
NA
Brief Summary
This study was designed to assess the safety and efficacy of neoadjuvant therapy with mitomycin C plus cisplatin (MP) in BRCA1-mutated ovarian cancer versus standard regimen (paclitaxel plus carboplat...
Detailed Description
The trial includes two arms, one of which is experimental arm with MP regimen chemotherapy that is compared with other arm with the standard TC regimen chemotherapy. To participate in this study, pati...
Eligibility Criteria
Inclusion
- histologically confirmed epithelial ovarian carcinoma or fallopian tubes carcinoma
- FIGO stage IIB, IIC, III, or IV disease
- BRCA1/BRCA2 germline mutation
Exclusion
- WHO performance status \>3
- FIGO early stage
- wt BRCA status
- cytological verification
Key Trial Info
Start Date :
October 1 2020
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
October 1 2025
Estimated Enrollment :
30 Patients enrolled
Trial Details
Trial ID
NCT04747717
Start Date
October 1 2020
End Date
October 1 2025
Last Update
February 11 2021
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
NMRC of Oncology named after N.N.Petrov of MoH of Russia
Saint Petersburg, Pesochny-2, St.-Petersburg, Russia, 197758